Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26168988
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Daptomycin for the Treatment of Infective Endocarditis: Results from European
Cubicin(®) Outcomes Registry and Experience (EU-CORE)
#MMPMID26168988
Guleri A
; Utili R
; Dohmen P
; Petrosillo N
; Piper C
; Pathan R
; Hamed K
Infect Dis Ther
2015[Sep]; 4
(3
): 283-96
PMID26168988
show ga
INTRODUCTION: The European Cubicin(®) Outcomes Registry and Experience
(EU-CORE(SM)) was a retrospective, non-interventional, multicenter study which
evaluated the safety and effectiveness of daptomycin therapy in patients with
Gram-positive infections including infective endocarditis (IE). METHODS: Data
from the EU-CORE registry were collected for patients with IE who had received at
least one dose of daptomycin between January 2006 and April 2012, across 18
countries in Europe (12), Latin America (5) and Asia (1). Clinical outcomes were
assessed as success (cured or improved), failure or non-evaluable. Adverse events
(AEs) were recorded during treatment and for up to 30 days post-treatment;
follow-up data were collected for 2 years. RESULTS: Of 6075 patients included in
the EU-CORE registry, 610 were diagnosed with IE as primary infection; 149
(24.4%) right-sided IE (RIE), 414 (67.9%) left-sided IE (LIE), and 47 (7.7%) with
both right- and left-sided IE (BRLIE). Overall clinical success was achieved in
80.0% of patients (RIE 88.6%, LIE 76.6% and BRLIE 82.9%). Success rates for
methicillin-resistant Staphylococcus aureus (MRSA) infections were 90.9%, 71.7%
and 66.6% in patients with RIE, LIE and BRLIE, respectively. The overall
sustained clinical success rate in patients followed for up to 2 years was 86.7%
(RIE 93.5%, LIE 88.3% and BRLIE 77.8%). AEs deemed possibly related to daptomycin
in the investigator's opinion were reported in 2 (1.3%) RIE, 18 (4.3%) LIE and 1
(2.1%) BRLIE patients. There were 11 (1.8%) patients (2 with RIE, 8 with LIE and
1 with BRLIE) with AEs of creatine phosphokinase elevation reported as possibly
related to daptomycin. CONCLUSION: Data from this real-world clinical setting
showed that daptomycin was well tolerated and effective for the treatment of LIE
and BRLIE in addition to RIE caused by Gram-positive bacteria, including MRSA.
Two-year follow-up data showed that a high proportion of patients had a sustained
response.
free
free
free
